Atara Biotherapeutics, Inc. (ATRA) Income Statement
ATRA 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsATRA revenue and net income
Where ATRA's revenue goes
2025Each bar shows an amount and its share of revenue. ATRA kept 27.1% of revenue as net income.
ATRA profit margins
ATRA growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | −6.3% | +23.9% | +102.4% | — |
| Gross profit | −7.8% | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
ATRA quarterly EPS vs estimates
Atara Biotherapeutics beat the analyst EPS estimate in 6 of the last 8 quarters. Next report: November 11, 2026.
ATRA income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $120.8M | $128.9M | $8.6M | $63.6M | $20.3M | $3.6M | $0 | $0 | $0 | $0 |
| Cost of revenue | $21.2M | $21.0M | $8.9M | $270.0M | $11.4M | $9.9M | $8.1M | $3.8M | $956,000 | $383,000 |
| Gross profit | $99.6M | $107.9M | −$313,000 | −$206.4M | $20.3M | −$9.9M | −$8.1M | −$3.8M | −$956,000 | −$383,000 |
| Research & development | $37.4M | $151.5M | $224.8M | $272.5M | $282.0M | $244.7M | $216.1M | $167.5M | $81.2M | $56.5M |
| Sales, general & admin | $26.3M | $39.9M | $52.0M | $68.1M | $78.8M | $64.4M | $79.6M | $69.7M | $40.3M | $24.7M |
| Total operating expenses | $63.7M | $191.4M | $275.7M | $74.1M | $360.8M | $309.1M | $295.7M | $237.1M | $121.5M | $81.2M |
| Operating income | $35.9M | −$83.4M | −$276.0M | −$280.5M | −$340.5M | −$309.1M | −$295.7M | −$237.1M | −$121.5M | −$81.2M |
| Interest income | $683,000 | $2.1M | $4.8M | $2.0M | $367,000 | $2.4M | $4.7M | $6.4M | $2.0M | $2.2M |
| Interest expense | $3.8M | $4.6M | $5.3M | $373,000 | $9.7M | $10.8M | $11.8M | $0 | $0 | $0 |
| Income before taxes | $32.7M | −$85.4M | −$276.1M | −$228.3M | −$340.1M | −$306.6M | −$291.0M | −$230.7M | −$119.5M | −$79.0M |
| Income taxes | $31,000 | −$12,000 | $15,000 | $12,000 | $46,000 | $15,000 | $12,000 | −$44,000 | −$14,000 | $10,000 |
| Net income | $32.7M | −$85.4M | −$276.1M | −$228.3M | −$340.1M | −$306.6M | −$291.0M | −$230.7M | −$119.5M | −$79.0M |
| EBITDA | $38.6M | −$75.7M | −$266.0M | −$222.3M | −$331.1M | −$300.7M | −$288.6M | −$233.4M | −$120.6M | −$80.9M |
| EPS (diluted) | $3.02 | −$7.45 | −$65.50 | −$68.07 | −$67.71 | −$53.65 | −$108.19 | −$131.00 | −$51.03 | −$54.83 |
| Gross margin | 82.4% | 83.7% | −3.7% | −324.7% | 100.0% | −277.8% | — | — | — | — |
| Operating margin | 29.7% | −64.7% | −3,219.5% | −441.2% | −1,673.9% | −8,700.8% | — | — | — | — |
| Net margin | 27.1% | −66.2% | −3,220.9% | −359.1% | −1,672.3% | −8,632.3% | — | — | — | — |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $630,000 | $516,000 | $1.6M | $3.5M | $17.6M | $98.1M | $32.8M | $40.2M | $28.6M | $27.4M | $4.3M | $2.1M |
| Cost of revenue | $191,000 | $124,000 | $104,000 | $115,000 | $554,000 | $20.4M | $6.8M | $7.6M | $4.6M | $2.0M | $3.2M | $2.6M |
| Gross profit | $439,000 | $392,000 | $1.5M | $3.3M | $17.0M | $77.7M | $26.0M | $32.6M | $24.0M | $25.4M | $1.1M | −$477,000 |
| Research & development | $1.3M | $164,000 | $223,000 | $2.9M | $7.3M | $27.4M | $28.7M | $43.9M | $33.3M | $45.5M | $44.0M | $56.9M |
| Sales, general & admin | $3.8M | $3.6M | $4.3M | $4.0M | $5.9M | $11.5M | $9.4M | $10.4M | $8.9M | $11.1M | $11.5M | $12.2M |
| Total operating expenses | $5.2M | $3.8M | $4.1M | $6.9M | $13.8M | $38.9M | $38.2M | $54.3M | $42.2M | $56.6M | $54.4M | $69.1M |
| Operating income | −$4.7M | −$3.4M | −$2.6M | −$3.6M | $3.2M | $38.8M | −$12.2M | −$21.8M | −$18.2M | −$31.2M | −$53.3M | −$69.6M |
| Interest income | $78,000 | $54,000 | $100,000 | $204,000 | $143,000 | $236,000 | $597,000 | $459,000 | $450,000 | $604,000 | $711,000 | $1.2M |
| Interest expense | $191,000 | $830,000 | $894,000 | $909,000 | $972,000 | $1.0M | $1.0M | $1.2M | $1.3M | $1.2M | $1.2M | $1.4M |
| Income before taxes | −$4.8M | −$4.1M | −$3.4M | −$4.3M | $2.4M | $38.0M | −$12.7M | −$21.9M | −$19.0M | −$31.7M | −$60.4M | −$69.8M |
| Income taxes | $1,000 | — | — | $28,000 | $3,000 | — | −$19,000 | −$17,000 | $171.4M | $24,000 | $11,000 | −$19,000 |
| Net income | −$4.8M | −$4.1M | −$3.4M | −$4.3M | $2.4M | $38.0M | −$12.7M | −$21.9M | −$19.0M | −$31.8M | −$60.5M | −$69.8M |
| EBITDA | −$4.6M | −$3.3M | −$2.5M | −$3.3M | $3.6M | $40.8M | −$10.6M | −$19.5M | −$16.5M | −$29.2M | −$58.1M | −$67.2M |
| EPS (diluted) | −$0.32 | −$0.29 | −$0.35 | −$0.32 | $0.19 | $3.50 | −$1.19 | −$2.93 | −$3.10 | −$0.23 | −$14.00 | −$16.50 |
| Gross margin | 69.7% | 76.0% | 93.5% | 96.7% | 96.8% | 79.2% | 79.3% | 81.1% | 83.8% | 92.7% | 25.7% | −22.3% |
| Operating margin | −749.2% | −652.9% | −160.7% | −103.5% | 18.2% | 39.5% | −37.3% | −54.1% | −63.7% | −114.2% | −1,253.0% | −3,255.9% |
| Net margin | −767.3% | −803.3% | −213.5% | −124.6% | 13.6% | 38.7% | −38.8% | −54.5% | −66.5% | −116.1% | −1,421.7% | −3,264.6% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in ATRA's financial statements (latest annual report filed March 16, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
ATRA financial results
In fiscal year 2025 (ended December 31, 2025), Atara Biotherapeutics reported revenue of $120.8 million, down 6.3% from the year before. It had net income of $32.7 million, a net profit margin of 27.1%. Diluted earnings per share came to $3.02. Over five years revenue grew at an average rate of 102.4% a year.
See the ATRA stock overview for the latest quote and news, or the ATRA chart for price history and technical indicators.
ATRA income statement FAQ
What is Atara Biotherapeutics's annual revenue?
Atara Biotherapeutics reported total revenue of $120.8 million for fiscal year 2025, which ended on December 31, 2025. That was down 6.3% from $128.9 million the previous year.
Is Atara Biotherapeutics profitable?
Yes. Atara Biotherapeutics reported net income of $32.7 million in fiscal 2025, a net profit margin of 27.1%; its operating margin was 29.7%.
What is Atara Biotherapeutics's gross margin?
Atara Biotherapeutics's gross margin was 82.4% in fiscal 2025: for every $100 of revenue, Atara Biotherapeutics kept $82 after the direct cost of its products and services.
How much does Atara Biotherapeutics spend on research and development?
Atara Biotherapeutics spent $37.4 million on research and development in fiscal 2025, 31.0% of revenue.
How fast is Atara Biotherapeutics growing?
Revenue grew 102.4% a year on average over the last five fiscal years, from $3.6 million to $120.8 million.
What are Atara Biotherapeutics's earnings per share?
Atara Biotherapeutics earned $3.02 per diluted share in fiscal 2025, compared with $-7.45 a year earlier.
When will Atara Biotherapeutics report its next earnings?
Atara Biotherapeutics is expected to report results for the quarter ending September 30, 2026 on November 11, 2026.
When does Atara Biotherapeutics's fiscal year end?
Atara Biotherapeutics's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 16, 2026.